Royalty Pharma plc Class A Ordinary Shares (RPRX) Stock Price
RPRXStock
$60.96+67.75%52W
Market Cap$35.22B
P/E45.47x
PEG Ratio1.42
Div yield2.96%
Beta0.39
RPRX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)14.96%
Price vs S&P 500 (4W)5.64%
PEG Ratio1.42
VGM Score52.25
P/E Ratio (Annual)45.47x
Indicated Dividend Yield (Annual)2.96%
RPRX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.27 | $1.32 | +3.85%(+$0.05) | |
| Q1 2026 | $1.18 | $1.30 | +9.39%(+$0.11) | |
| Q4 2025 | $1.33 | $1.47 | +9.95%(+$0.13) | |
| Q3 2025 | $1.04 | $1.17 | +12.53%(+$0.13) | |
| Q2 2025 | $1.03 | $1.14 | +10.48%(+$0.11) |
RPRX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.19
4.19
4.19
4.19
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RPRXRoyalty Pharma plc Class A Ordinary Shares | D | D | A | 13.8x | 10.0% | — | -12.1% | $60.96 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties, generating recurring revenue from fixed payments tied to the sales of commercial medications. The company receives royalties from a diversified portfolio of 35+ approved products across oncology, neurology, and rare genetic diseases, plus 10 development-stage candidates from major pharmaceutical companies including AbbVie, Johnson & Johnson, Biogen, and Vertex. This business model provides predictable cash flows from established market-leading drugs without the operational risks of drug development or commercialization.